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Abstract Cardiac output (Q) and stroke volume (VS)
represent primary determinants of cardiovascular perfor-
mance and should therefore be determined for performance
diagnostics purposes. Since it is unknown, whether mea-
surements of Q and VS can be performed by means of
InnocorTM during standard graded exercise tests (GXTs),
and whether current GXT stages are sufficiently long for
the measurements to take place, we determined Q and VS at
an early and late point in time on submaximal 2 min GXT
stages. 16 male cyclists (age 25.4 ± 2.9 years, body mass
71.2 ± 5.0 kg) performed three GXTs and we determined
Q and VS after 46 and 103 s at 69, 77, and 85% peak
power. We found that the rebreathings could easily be
incorporated into the GXTs and that Q and VS remained
unchanged between the two points in time on the same
GXT stage (69% peak power, Q: 18.1 ± 2.1 vs.
18.2 ± 2.3 l min-1, VS: 126 ± 18 vs. 123 ± 21 ml; 77%
peak power, Q: 20.7 ± 2.6 vs. 21.0 ± 2.3 l min-1, VS:
132 ± 18 vs. 131 ± 18 ml; 85% peak power, Q:
21.6 ± 2.4 vs. 21.8 ± 2.7 l min-1, VS: 131 ± 17 vs.
131 ± 22 ml). We conclude that InnocorTM may be a
useful device for assessing Q and VS during GXTs, and that
the adaptation of Q and VS to exercise-to-exercise
transitions at moderate to high submaximal power outputs
is fast enough for 1 and 2 min GXT stage durations.
Keywords Performance diagnostics  Cardiac function 
Haemodynamics  Steady state  Graded exercise tests 
Inert gas rebreathing
Introduction
Conventional cardiovascular performance diagnostics
relies on heart rate, blood lactate concentration, perceived
exertion, respiratory (oxygen consumption, carbon dioxide
output), and ventilatory (breathing frequency, tidal vol-
ume) parameters. Changes in these parameters over time,
in particular, with respect to maximal oxygen consumption,
are used to determine performance improvements after
training. Nevertheless, (maximal) oxygen consumption
does not constitute the primary determinant of cardiovas-
cular performance. In fact, it is believed that in healthy
humans, a high maximal oxygen consumption primarily
depends on maximal oxygen delivery to the exercising
muscles (Saltin and Calbet 2006), and therefore on a high,
maximal cardiac output (Calbet et al. 2004). Consequently,
we propose that for performance diagnostics purposes,
cardiac output and stroke volume should standardly be
determined under exercise conditions and subsequently
related to the conventional respiratory, ventilatory, and
metabolic parameters.
However, cardiac output and stroke volume determina-
tions must meet several requirements in order to be viable
for incorporation into standard exercise tests. A central
requirement is that the employed measurement method is
valid, reliable, and safe. Furthermore, it should not pose
any major discomfort to the participants. In addition, the
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employed method should be easily applicable to standard
graded exercise test (GXT) protocols (Bentley et al. 2007).
One promising non-invasive approach having the potential
to fulfil these requirements is nitrous oxide (inert gas)
rebreathing, which can be performed using the recently
introduced InnocorTM system (Innovision, Odense, Den-
mark). Validation of the InnocorTM cardiac output mea-
surement against direct Fick showed a good accordance
(Agostoni et al. 2005; Gabrielsen et al. 2002; Peyton and
Thompson 2004). In addition, we recently found that car-
diac output determinations using InnocorTM are reliable
(Fontana et al. 2009). While it was shown that cardiac
output determinations by InnocorTM are valid and reliable,
it is still unknown whether the measurement point in time
during a typical GXT stage (i.e. 2 min) affects the outcome
of the cardiac output measurement in healthy participants,
i.e. whether cardiac output differs if measured within the
first minute after the exercise-to-exercise transitions com-
pared to when measured at the end of the 2 min stages.
Evidence for quick adjustments of cardiac output to
increased power comes from the examination of haemo-
dynamics during rest-to-exercise transitions in healthy
participants by determining cardiac function on a beat-by-
beat basis, using Doppler ultrasound (De Cort et al. 1991)
or the model flow method (Lador et al. 2006, 2008). These
studies showed that when increasing power from rest to 50,
80, or 100 W (i.e. ‘‘rest-to-exercise’’ transitions), a steady
state for cardiac output is quickly reached (e.g. within the
first minute). However, all power outputs were not higher
than 100 W, and only rest-to-exercise, but not exercise-to-
exercise transitions were examined. Furthermore, these
studies do not provide any information about intra-stage
haemodynamics, i.e. the evolvement of cardiac output,
stroke volume, and heart rate on the single stages of
moderate and high submaximal power during standard
GXTs.
Therefore, we aimed at determining cardiac output and
stroke volume using inert gas rebreathing by means of
InnocorTM, as well as heart rate, during standard GXTs
after 46 and 103 s at 69, 77, and 85% peak power in
healthy male participants. We hypothesised that these
measurements are feasible for stage durations of 2 min, and
that on each test stage no differences with respect to car-
diac output and stroke volume exist between the two points
in time (46 and 103 s).
Methods
Participants
We recruited 16 recreationally trained male cyclists. The
participants’ individual values are presented in Table 1. All
participants were healthy and non-smoking. In order to
avoid fatigue-related effects on test performance, no
strenuous physical activity was allowed for 48 h prior to
the tests. Starting 2 weeks before the examinations, the
participants recorded their physical activity in a training
log and continued to do so until the end of the study. Based
on the training log, we observed that the training volume
was similar throughout the study. We informed the par-
ticipants about all procedures involved and about the
Table 1 Values of body mass,
height, age, peak oxygen
consumption, and peak power
for 16 male cyclists
SD standard deviation
Participant Body mass (kg) Height (m) Age (years) Peak oxygen
consumption (l min-1)
Peak power (W)
1 62.5 1.611 25.3 4.48 360
2 71.6 1.750 22.1 4.40 390
3 76.0 1.877 22.2 4.39 390
4 69.5 1.775 26.5 4.60 390
5 84.4 1.902 22.3 4.68 390
6 74.7 1.820 26.1 3.98 370
7 70.7 1.830 22.1 4.40 400
8 70.2 1.778 26.9 4.11 400
9 70.8 1.815 22.4 4.71 430
10 66.9 1.792 25.4 4.54 370
11 74.8 1.795 26.9 4.38 373
12 73.9 1.866 28.3 4.45 400
13 65.8 1.745 26.9 4.05 348
14 71.2 1.795 30.4 4.43 350
15 68.0 1.785 22.5 4.47 403
16 68.9 1.880 30.1 4.36 375
Mean ± SD 71.2 ± 5.0 1.801 ± 0.069 25.4 ± 2.9 4.40 ± 0.21 384 ± 22
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associated risks. After the completion of a routine health
questionnaire, the participants gave written informed con-
sent. The study was approved by the human ethics com-
mittee of the ETH Zurich.
Study design and experimental setup
All participants performed three GXTs to volitional
exhaustion on a cycle ergometer (Ergoselect 200 K, Erg-
oline, Bitz, Germany). In all participants, test 1 (increments
of 30 W every 2 min until volitional exhaustion) served for
determining peak power and maximal gas exchange (In-
nocorTM, Innovision, Odense, Denmark). During test 1, we
also determined the freely chosen pedalling rate
(C70 min-1), which was then held constant throughout all
tests. In tests 2 and 3, we non-invasively determined car-
diac output by inert gas rebreathing (InnocorTM, Innovi-
sion, Odense, Denmark) at 69, 77, and 85% peak power
attained in test 1. The respective rebreathings were per-
formed in a randomised order, either during the first or the
second minute on each stage (either in test 2 or 3).
Throughout tests 2 and 3, we continuously recorded heart
rate and oxygen consumption. All tests took place within a
time frame of 2 weeks, except for subject number 9, who
was tested 5 weeks apart, due to a common cold.
On the first examination day, we informed the partici-
pants about the upcoming procedures. Then, they per-
formed test 1. Test 2 was either carried out 1 h after test 1
or on day 2. Test 3 was always conducted on day 2, either
1 h after test 2 or as the only test performed. Before tests 2
and 3, we equipped the participants with a heart rate
monitor (S610i, Polar Electro, Kempele, Finland), a face-
mask (Hans Rudolph, Shawnee, KS, USA), and an anti-
bacterial filter (PALL PF30-S, Pall, East Hills, NY, USA).
We then connected the participants to the InnocorTM
device. Before test 2, the participants practiced the
rebreathing procedure with ambient air during three
attempts, as described earlier (Fontana et al. 2009). Sub-
sequently, we measured cardiac output at rest. Two min-
utes after the rebreathing under resting conditions, cycling
started at 54% peak power for 2 min (‘‘warm-up’’). Then,
we increased power to 69% peak power for 2 min. After-
wards, power was raised twice by 8% peak power for
2 min. Cardiac output determinations were performed at
69, 77, and 85% peak power. All measurements were
performed by the same investigator.
Determination of cardiac output
Rebreathings were performed in a closed system, which
consisted of a three-way respiratory valve connecting a
facemask, an anti-static rubber bag, and an infrared
photoacoustic gas analyser (Clemensen et al. 1994). The
participants rebreathed a gas mixture of nitrous oxide
(0.5%) and sulphur hexafluoride (0.1%) in oxygen, diluted
with atmospheric air, from an anaesthesia bag of size 3–6 l,
depending on the individual participant’s predicted vital
capacity (Quanjer et al. 1993). At rest, the settings of the
InnocorTM were a 20% bolus volume (volume of gas
mixture, consisting of nitrous oxide, sulphur hexafluoride,
and oxygen), a rebreathing frequency of 20 min-1, and a
total gas mixture volume of 40% of the predicted vital
capacity (Quanjer et al. 1993). The InnocorTM software
adjusted these settings dynamically under exercise condi-
tions, considering a maximal bolus volume of 40%, a
minimal oxygen content of 13%, and a maximal carbon
dioxide content of 15%, taking into account the partici-
pants’ individual breathing frequencies. Rebreathing was
typically performed over 5–8 breaths, of which the last 2–3
breaths were used for the calculation of pulmonary blood
flow and cardiac output, taking into account estimated
shunt flow (Gabrielsen et al. 2002). The calculation of
cardiac output was performed according to the manufac-
turer. For detecting the single breaths during the rebrea-
things, we standardly used end-tidal carbon dioxide
concentrations. This procedure has been shown to give
reliable measurements of pulmonary blood flow and car-
diac output, even at peak exercise (Fontana et al. 2009).
However, during some rebreathings, the detection of the
breaths was facilitated using end-tidal oxygen concentra-
tions. Employing this procedure, all rebreathings could be
used in order to calculate cardiac output. Each rebreathing
lasted between 8 and 10 s. Since the mean transit time of a
dye marker after 60–120 s of high intensity exercise
appears to be in the range of 12 s (Krustrup et al. 2009), it
is unlikely that recirculation of nitrous oxide occurred.
Additionally, we checked online breath-by-breath
rebreathing gas concentrations during each cardiac output
measurement in order to detect possible elevations in
nitrous oxide concentrations due to recirculating gas. We
observed no nitrous oxide gas recirculation during all
measurements. Thus, a recirculation-based measurement
bias should be excluded.
Calculations
For each participant, we calculated peak power as ‘‘power
on the last completed stage ? t(s)/120 s 9 30 W’’. For
peak oxygen consumption, we took the highest mean over
30 s achieved in test 1. During tests 2 and 3, the exact
rebreathing points in time relative to test stage duration
were calculated by determining the point in time of the
valve opening and adding the time elapsed until complete
mixing of the rebreathing gases was achieved. Therefore,
rebreathing points in time were on average 46 or 103 s
either in test 2 or 3 on the three test stages (Table 2). We
Eur J Appl Physiol (2010) 108:573–580 575
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calculated stroke volume by dividing cardiac output by
heart rate. For heart rate, we took the 10 s mean recorded
right after the rebreathings.
Statistical analysis
We checked the data for normality by Q–Q plot, and
analysed it for statistical significance (P \ 0.05) using
SPSS 16.0 (SPSS, Chicago, IL, USA). For comparisons of
cardiac output, stroke volume, and heart rate between 46
and 103 s on each single stage, we used Student’s paired t
test. For comparisons between stages, ANOVA repeated
measures with Bonferroni correction were used. Since we
did not perform multiple comparisons, the occurrence of a
type I error is unlikely and the aforementioned analyses
were chosen instead of a two-way ANOVA (time 9 stage).
Results
Cardiac output
Cardiac output measurements by InnocorTM inert gas
rebreathing could be performed at 69, 77, and 85% peak
power at both, 46 and 103 s after the stage transitions.
Furthermore, cardiac output for the 16 participants did not
differ between the early (46 s) and late (103 s) rebreathing
points in time on all three test stages (69, 77, and 85% peak
power; Table 3; Fig. 1), and the adjustments of cardiac
output between 46 and 103 s were the same after incre-
ments of 15 (from 54 to 69% peak power) and 8% peak
power (from 69 to 77% and from 77 to 85% peak power;
Table 3). Additionally, cardiac output increased signifi-
cantly from rest to 69% of peak power at 46 and 103 s
(Table 3). Between 69 and 77% peak power, cardiac output
further increased significantly with respect to both mea-
surement points in time, whereas between 77 and 85% peak
power, cardiac output was the same (Table 3).
Stroke volume
Stroke volume was not significantly different between the
two measuring points in time at 69, 77, and 85% peak
power (Table 3). Furthermore, stroke volume significantly
increased when transitioning from rest to 69% peak power,
both when measured at 46 and 103 s (Table 3). At 77 and
85% peak power, stroke volume was not different than at
69% peak power (Table 3).
Heart rate
Heart rate was significantly higher after 103 than after 46 s
at 69% peak power (Table 3). Both, at 77 and 85% peak
power, heart rate was not different between 46 and 103 s
(Table 3). Heart rate rose from rest to 69, 77, and 85%
peak power with respect to both measurement points in
time (Table 3).
Discussion
In this study, we have shown that it is feasible to non-
invasively determine cardiac output by inert gas rebreath-
ing at 46 and 103 s on moderate and high intensity
submaximal GXT stages, using the InnocorTM device. This
study also shows that cardiac output of recreationally
trained cyclists does not change between these two points
in time at 69, 77, and 85% peak power (Fig. 2). While
stroke volume, too, is not different when determined at 46
and 103 s after power stage transitions, heart rate is higher
after 103 than after 46 s at 69% peak power, but is
unchanged between the two measurement points in time at
both 77 and 85% peak power. Our finding that at different
power stages of standard graded cycling exercise tests,
non-invasive measurements by inert gas rebreathing using
the InnocorTM device can easily be performed in healthy,
recreationally trained male cyclists, might offer a new
dimension to current cardiovascular performance diagnos-
tics. Since peak oxygen consumption is mainly determined
by peak cardiac output (Fick 1870), and the latter mainly
depends on a large stroke volume (Levine 2008), central
haemodynamic improvements after training could be
Table 2 Individual rebreathing points in time (s) after exercise-to-
exercise transitions at 69, 77, and 85% peak power for 16 male
cyclists
Participant 46 s 103 s
1 38 119
2 52 104
3 36 97
4 36 96
5 37 98
6 46 97
7 45 104
8 52 107
9 45 104
10 64 101
11 46 106
12 50 103
13 50 104
14 50 104
15 49 105
16 48 98
Average ± SD 46 ± 7 103 ± 5
SD standard deviation
576 Eur J Appl Physiol (2010) 108:573–580
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detected in parallel with gas exchange in future standard
cardiovascular diagnostic tests. This possibility might
prove useful in better defining the link between changes in
metabolic demand and cardiovascular control following
exercise and/or inactivity, and help physiologists as well as
coaches to improve the supervision of athletic
performance.
Our result that at 69, 77, and 85% peak power, cardiac
output in healthy male cyclists is the same at 46 and 103 s
after reaching the power stage (Fig. 2) lends further cre-
dence to earlier studies investigating the haemodynamic
response to rest-to-exercise transitions. In these studies, itT
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Fig. 1 Cardiac output measurement protocol (tests 2 and 3).
Rebreathings were performed either at 46 or 103 s after the power
stage transitions at 69, 77, and 85% peak power, as assessed during
test 1. On each stage, the measurement point in time (46 or 103 s) was
randomised (horizontal black arrows). Vertical black arrows cardiac
output measurements, vertical dashed arrows learning trials (rebrea-
things with ambient air, only before test 2)
Fig. 2 Individual values of cardiac output at 46 and 103 s at 69, 77,
and 85% peak power for 16 male cyclists. The solid line indicates the
line of identity
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was shown that a steady state for cardiac output is attained
between 30 (Lador et al. 2006, 2008) and 60 s (De Cort
et al. 1991). Also, Davies et al. (1972) found a rapid
adjustment of cardiac output after increasing power (i.e.
walking velocity and gradient) during treadmill exercise,
using a modified indirect Fick method. However, the
observed halftime for cardiac output adaptation after
increasing power from moderate (*40% maximum aero-
bic power) to heavy exercise (*80% maximum aerobic
power) was 20 s. In our study, the respective halftime
seems to be in the range of 12 s, indicating slightly faster
cardiac output kinetics than in Davies et al. (1972),
although more measurement points in time would be
required to obtain comprehensive kinetic data.
We also observed that cardiac output in healthy male
cyclists is the same at 46 and 103 s after reaching the
power stage, irrespective of the size of the preceding power
increment (up to 15% peak power) between stages (15%
from 54 to 69% peak power, 8% from 69 to 77%, and 8%
from 77 to 85%). Therefore, it seems that small power
increments (up to 15% peak power) between two stages
may not influence the evolution of cardiac output on the
higher stage, although we did not explicitly examine car-
diac output on stages with equal power after increments of
different sizes. Furthermore, the evolution of cardiac out-
put after increasing power during a GXT seems not to be
influenced by a levelling off of cardiac output, which in our
experiments occurred between 77 and 85% peak power.
Our observed flattening of the cardiac output–power rela-
tionship at high submaximal intensities is consistent with
the findings of Calbet et al. (2007, dye-dilution) and
Mortensen et al. (2005, Fick principle), who found cardiac
output to level off after 84 and 80% peak power,
respectively.
Evidence for rapid adjustments of stroke volume after
stage transitions is that stroke volume was not significantly
different between 46 and 103 s at 69, 77, and 85% peak
power. Furthermore, stroke volume at 69% peak power
tended to be higher after 46 s than at 103 s. This finding
was accompanied by a significantly lower heart rate. Since
stroke volume was calculated by dividing cardiac output by
heart rate, the lack of statistical significance concerning the
potentially lower stroke volume at 103 s might be a sta-
tistical issue. This assumption may be supported by the
data of Davis et al. (2005), who estimated stroke volume
during GXTs with different increment durations, i.e. 1 and
4 min. They found that stroke volume at submaximal
power was higher for the 1-min than for the 4-min protocol.
However, the rapid inter-stage adjustment of stroke volume
was not compromised by the levelling off of stroke volume
between 69 and 85% peak power. In fact, in our experi-
ments, stroke volume increased significantly when transi-
tioning from rest to 69% peak power, but was the same at
69, 77, and 85% peak power. These findings are consistent
with those of Calbet et al. (2007), who reported stroke
volume to rise after the transition from unloaded pedalling
to submaximal exercise, and then reach maximal values
beyond 64% peak power. Furthermore, our data confirm
the findings of Davies et al. (1972), who found stroke
volume to be similar between 40 and 80% of maximal
aerobic power. However, according to our results, stroke
volume might reach a plateau as late as at 77% peak power,
since stroke volume tended to be lower at 69 compared to
77% of peak power.
The encountered haemodynamic pattern leads us to
speculate that at 69% peak power, maximal stroke volume
may not be fully exploited. Thus, at this moderate intensity,
stroke volume may still possess a reserve for further
increases that could serve to quickly adjust cardiac output
after increasing power by 15% from 54 to 69% peak power.
The fact that at 69% peak power heart rate was different
between 46 and 103 s may be further indicative of stroke
volume’s role in mediating the rapid adjustment of cardiac
output after the stage transition from 54 to 69% peak
power. Further support for our speculation that stroke
volume might mediate the initial increase in cardiac output
comes from De Cort et al. (1991), who reported that stroke
volume quickly reacts to increases of power, and then tends
to decrease after 90–120 s of constant power exercise, with
cardiac output remaining unchanged. However, at exercise
intensities of 77 and 85% peak power, peak stroke volume
seems to be fully exploited. Accordingly, stroke volume at
these intensities might not be further increased to raise
cardiac output after power stage transitions. Therefore,
cardiac output adjustments after increasing power from 77
to 85% peak power may solely rely on the increase in heart
rate. Indeed, our data indicate that heart rate at 77 and 85%
peak power is the same at 46 and 103 s. The quicker heart
rate adjustment at high intensities may possibly be facili-
tated by the pronounced increase of sympathetic nervous
system activity above 60–70% peak oxygen consumption
(Nakamura et al. 1993; Saito and Nakamura 1995;
Yamamoto et al. 1991) with concomitant pronounced
increases of norepinephrine and epinephrine concentrations
(Escourrou et al. 1984; Nakamura et al. 1993; Orizio et al.
1988). This positive inotropic effect of the increased
sympathetic drive to the heart is likely not to further raise
stroke volume, since at 77 and 85% peak power maximal
stroke volume was reached.
Methodological considerations
Three methodological issues must be considered. The first
one concerns the rebreathing points in time (46 ± 7 and
103 ± 5 s). They result from averaging the individual
points in time (Table 2) across all participants, and are
578 Eur J Appl Physiol (2010) 108:573–580
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explained by the fact that the point in time of the first
breath, of which the end-tidal nitrous oxide concentration
was used for fitting the regression line, slightly varied
between participants as well as within participants between
the tests. Two reasons explain this variation. The first
reason is that the point in time of complete gas mixing
(respiratory tracts, anaesthesia bag, mask, and valves)
during inert gas rebreathing by InnocorTM slightly differed
within the tests (within and between the participants). In
our study, complete gas mixing was typically achieved
within the first 3–5 breaths after the start of the rebreathing
procedure. Complete gas mixing is required for reliably
calculating pulmonary blood flow (from which cardiac
output is determined), since the calculation of pulmonary
blood flow is based on a regression line through end-tidal
nitrous oxide concentrations versus time. The second rea-
son for the variation of the individual rebreathing points in
time is that depending on the participants’ breathing pat-
tern, the start of the rebreathing procedure varied by 1–5
breaths (within and between the participants). Hence, based
on these individual measurement delays, the rebreathing
points in time (averaged within and between the partici-
pants) were 46 and 103 s. The second methodological issue
concerns a possible measurement bias which might be
caused by recirculation of nitrous oxide. In our experi-
ments, the rebreathing manoeuvres at 103 s did not lead to
nitrous oxide gas recirculation at 46 s. Thus, time intervals
of approximately 60 s between measurements point in time
(and thus stage durations lasting 60 s) seem to be safe.
However, for time intervals below 60 s, recirculation of
nitrous oxide cannot be excluded. The third methodological
consideration concerns the power stages, at which we
performed the rebreathings (69, 77, and 85% peak power).
These three power stages, corresponding to moderate to
high exercise intensity levels before and after a hypothetic
levelling off of cardiac output (Mortensen et al. 2005),
were chosen because we speculated that a levelling off
could influence the intra-stage adaptation of cardiac output
and stroke volume. Furthermore, increments corresponding
to 8% peak power were chosen because this value repre-
sents approximately 30 W increments in GXTs performed
by experienced male road cyclists (Amann et al. 2004).
We conclude that during standard GXTs, the determi-
nation of cardiac output and stroke volume by InnocorTM
inert gas rebreathing at moderate to high submaximal
power outputs in healthy, recreationally trained male
cyclists is easily feasible for performance diagnostics
purposes. Furthermore, our results indicate that during
standard GXTs the haemodynamic response to power stage
transitions from 54 to 69%, 69 to 77%, and 77 to 85% peak
power is fast enough to ensure same values of cardiac
output and stroke volume at 46 and 103 s on the higher
stage. Due to this rapid adjustment of cardiac output, stage
durations lasting less than 60 s are possible. Finally, since
power increment sizes of 8 and 15% at submaximal levels
seem not to affect intra-stage adjustments of cardiac output
on the higher stages, these power increments may be well
suited to assess submaximal cardiac output during GXTs.
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